Cleara Biotech B.V.

Cleara Biotech is a biopharmaceutical research and development company that develops peptide-based therapies to selectively eliminate p53-impaired cells. The company utilizes a proprietary platform technology to create compounds like CL04183, which induce apoptosis in cancer cells regardless of mutation site. Its primary focus is on treating solid tumors and hematological malignancies, including metastatic colon cancer and triple-negative breast cancer.